search
Back to results

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (POLAR BEAR)

Primary Purpose

DLBCL, Diffuse Large B Cell Lymphoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
R-pola-mini-CHP
R-mini-CHOP
Sponsored by
Nordic Lymphoma Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for DLBCL focused on measuring DLBCL, Diffuse Large B Cell Lymphoma

Eligibility Criteria

75 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment

  • Histologically confirmed lymphoma belonging to one of the following subtypes:

    1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma
    2. follicular lymphoma grade 3B
    3. T-cell/histiocyte-rich LBCL
    4. primary cutaneous DLBCL, leg type
    5. EBV-positive DLBCL, NOS
    6. primary mediastinal LBCL
    7. high grade B-cell lymphoma with MYC/BCL2 rearrangement
  • Stage II-IV disease
  • At least 1 measurable site of disease (>1.5 cm long axis)
  • No previous treatment for lymphoma
  • WHO performance status 0 - 3 (Grade 3 if related to DLBCL)
  • Written informed consent

Exclusion Criteria:

  • Severe cardiac disease: NYHA grade 3-4
  • CNS involvement at diagnosis
  • Uncontrolled serious infection
  • Impaired liver (transaminases > 3x normal upper limit or bilirubin > 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (GFR<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment.
  • Absolute neutrophil count (ANC) <1000 cells/µL or platelets <100,000 cells/µL, unless due to lymphoma
  • Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment
  • Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study
  • Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab

Sites / Locations

  • Department og Hematology, Aalborg University HospitalRecruiting
  • Department of Hematology, Aarhus University HospitalRecruiting
  • Clinic of Hematology L-4241, RigshospitaletRecruiting
  • Sydvestjysk SygehusRecruiting
  • Herlev HospitalRecruiting
  • Regionshospitalet HolstebroRecruiting
  • Department of Hematology X, Odense University HospitalRecruiting
  • Department of Hematology, Zeeland University Hospital RoskildeRecruiting
  • Vejle SygehusRecruiting
  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterRecruiting
  • Kuopio University HospitalRecruiting
  • Oulu University HospitalRecruiting
  • Tampere University HospitalRecruiting
  • Turku University HospitalRecruiting
  • Centro di riferimento oncologico di AvianoRecruiting
  • Istituto Tumori "Giovanni Paolo II" I.R.C.C.S BariRecruiting
  • Ospedale San Gerardo di MonzaRecruiting
  • Azienda Ospedaliera Univeristaria Federico II di NapoliRecruiting
  • Istituto Nazionale Tumori "Fondazione Pascale" NapoliRecruiting
  • Azienda Ospedaliera San Camillo Forlanini di RomaRecruiting
  • IRCCS San Raffaele Scientific InstituteRecruiting
  • Azienda Sanitaria Universitaria Integrata di TriesteRecruiting
  • Azienda Sanitaria Universitaria Integrata di UdineRecruiting
  • Azienda Ospedaliera Universitaria Integrata VeronaRecruiting
  • Haukeland UniversitetshospitalRecruiting
  • Kalnes Hospital (Østfold)Recruiting
  • Akershus University HospitalRecruiting
  • Avd. for Kreftbehandling, Oslo universitetssykehusRecruiting
  • Avdeling for Blod- og Kreftsykdommer, Stavanger UniversitetssykehusRecruiting
  • University Hospital of North NorwayRecruiting
  • Kreftklinikken, St Olavs HospitalRecruiting
  • Sykehuset i VestfoldRecruiting
  • Medicinkliniken, Södra Älvsborg SjukhusRecruiting
  • Department of Hematology and Coagulation, Sahlgrenska University HospitalRecruiting
  • Department of Medicine, Halmstad Country HospitalRecruiting
  • Department of Internal Medicine, Kalmar County HospitalRecruiting
  • Hematologiska Kliniken, UniversitetssjukhusetRecruiting
  • Department of Oncology, Skåne University HospitalRecruiting
  • Center of Hematology, Karolinska University HospitalRecruiting
  • Department of Medicine, Sunderbyn HospitalRecruiting
  • Uddevalla SjukhusRecruiting
  • Cancercentrum, Norrlands universitetsjukhusRecruiting
  • Department of Oncology, Uppsala Academic HospitalRecruiting
  • Varberg HospitalRecruiting
  • Department of Oncology, Örebro University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Arm A - R-mini-CHOP

Arm B - R-pola-mini-CHP

Arm Description

Cycles 1-6, duration 21 days Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6

Cycles 1-6, duration 21 days Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6

Outcomes

Primary Outcome Measures

Progression-free survival (PFS).
The primary end point of this study is PFS. The null hypothesis is that pola-R-mini-CHP is equivalent to R-mini-CHOP. PFS is defined as the interval between registration date and date of documented progression or lack of response, first relapse, or death of any cause. Otherwise, patients will be censored at the last date they were known to be alive. For patients with PD as best response, PFS is defined as 1 day.

Secondary Outcome Measures

Full Information

First Posted
April 1, 2020
Last Updated
July 8, 2021
Sponsor
Nordic Lymphoma Group
Collaborators
Roche Pharma AG
search

1. Study Identification

Unique Protocol Identification Number
NCT04332822
Brief Title
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Acronym
POLAR BEAR
Official Title
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Recruiting
Study Start Date
August 19, 2020 (Actual)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
February 28, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nordic Lymphoma Group
Collaborators
Roche Pharma AG

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy and Switzerland, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin. The duration of the screening period is up to 4 weeks. The duration of active treatment is 18 weeks in both arms, and patients will be followed up to 36 months after end of treatment. Start of enrollment is planned in Q1 2020, and the last visit of the last patient included (end of trial) is estimated in Q1 2026.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
DLBCL, Diffuse Large B Cell Lymphoma
Keywords
DLBCL, Diffuse Large B Cell Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A - R-mini-CHOP
Arm Type
Active Comparator
Arm Description
Cycles 1-6, duration 21 days Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Arm Title
Arm B - R-pola-mini-CHP
Arm Type
Experimental
Arm Description
Cycles 1-6, duration 21 days Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6
Intervention Type
Drug
Intervention Name(s)
R-pola-mini-CHP
Intervention Description
Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6 Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6 Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6 Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6
Intervention Type
Drug
Intervention Name(s)
R-mini-CHOP
Intervention Description
Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Primary Outcome Measure Information:
Title
Progression-free survival (PFS).
Description
The primary end point of this study is PFS. The null hypothesis is that pola-R-mini-CHP is equivalent to R-mini-CHOP. PFS is defined as the interval between registration date and date of documented progression or lack of response, first relapse, or death of any cause. Otherwise, patients will be censored at the last date they were known to be alive. For patients with PD as best response, PFS is defined as 1 day.
Time Frame
2 years.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment Histologically confirmed lymphoma belonging to one of the following subtypes: diffuse large B-cell lymphoma, including transformation from an indolent lymphoma follicular lymphoma grade 3B T-cell/histiocyte-rich LBCL primary cutaneous DLBCL, leg type EBV-positive DLBCL, NOS primary mediastinal LBCL high grade B-cell lymphoma with MYC/BCL2 rearrangement Stage II-IV disease At least 1 measurable site of disease (>1.5 cm long axis) No previous treatment for lymphoma WHO performance status 0 - 3 (Grade 3 if related to DLBCL) Written informed consent Exclusion Criteria: Severe cardiac disease: NYHA grade 3-4 CNS involvement at diagnosis Uncontrolled serious infection Impaired liver (transaminases > 3x normal upper limit or bilirubin > 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (GFR<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment. Absolute neutrophil count (ANC) <1000 cells/µL or platelets <100,000 cells/µL, unless due to lymphoma Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mats Jerkeman
Phone
0046704973507
Email
mats.jerkeman@med.lu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman
Organizational Affiliation
Department of Oncology, Skåne University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department og Hematology, Aalborg University Hospital
City
Aalborg
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jakob Madsen
Email
jm@rn.dk
First Name & Middle Initial & Last Name & Degree
Jakob Madsen
Facility Name
Department of Hematology, Aarhus University Hospital
City
Aarhus
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judit Jörgensen
Email
Judit.Joergensen@aarhus.rm.dk
First Name & Middle Initial & Last Name & Degree
Judit Jörgensen
Facility Name
Clinic of Hematology L-4241, Rigshospitalet
City
Copenhagen
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Brown
Email
peter.brown@regionh.dk
First Name & Middle Initial & Last Name & Degree
Peter Brown
Facility Name
Sydvestjysk Sygehus
City
Esbjerg
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andriette Dessau-Arp
Email
Andriette.Dessau-Arp@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Andriette Dessau-Arp
Facility Name
Herlev Hospital
City
Herlev
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Gang
Email
anne.ortved.gang@regionh.dk
First Name & Middle Initial & Last Name & Degree
Anne Gang
Facility Name
Regionshospitalet Holstebro
City
Holstebro
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisa Pulczynski
Email
Elisa.Jacobsen.Pulczynski@aarhus.rm.dk
First Name & Middle Initial & Last Name & Degree
Elisa Pulczynski
Facility Name
Department of Hematology X, Odense University Hospital
City
Odense
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen Juul-Jensen
Email
karen.juul-jensen@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Karen Juul-Jensen
Facility Name
Department of Hematology, Zeeland University Hospital Roskilde
City
Roskilde
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Bjørn Poulsen
Email
cbpo@regionsjaelland.dk
First Name & Middle Initial & Last Name & Degree
Christian Bjørn Poulsen
Facility Name
Vejle Sygehus
City
Vejle
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Clausen
Email
Michael.Roost.Clausen@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Michael Clausen
Facility Name
Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
City
Helsinki
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sirpa Leppä
Email
sirpa.leppa@helsinki.fi
First Name & Middle Initial & Last Name & Degree
Sirpa Leppä
Facility Name
Kuopio University Hospital
City
Kuopio
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katja Marin
Email
Katja.marin@kuh.fi
First Name & Middle Initial & Last Name & Degree
Katja Marin
Facility Name
Oulu University Hospital
City
Oulu
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanne Kuitunen
Email
hanne.kuitunen@ppshp.fi
First Name & Middle Initial & Last Name & Degree
Hanne Kuitunen
Facility Name
Tampere University Hospital
City
Tampere
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marjukka Pollari
Email
marjukka.pollari@pshp.fi
First Name & Middle Initial & Last Name & Degree
Marjukka Pollari
Facility Name
Turku University Hospital
City
Turku
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sirkku Jyrkkiö
Email
sirkku.jyrkkio@tyks.fi
First Name & Middle Initial & Last Name & Degree
Sirkku Jyrkkiö
Facility Name
Centro di riferimento oncologico di Aviano
City
Aviano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Spina
First Name & Middle Initial & Last Name & Degree
Michele Spina
Facility Name
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S Bari
City
Bari
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Attilio Guarini
First Name & Middle Initial & Last Name & Degree
Attilio Guarini
Facility Name
Ospedale San Gerardo di Monza
City
Monza
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Anna Maria Bolis
First Name & Middle Initial & Last Name & Degree
Silvia Anna Maria Bolis
Facility Name
Azienda Ospedaliera Univeristaria Federico II di Napoli
City
Napoli
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Severino
First Name & Middle Initial & Last Name & Degree
Alessandro Severino
Facility Name
Istituto Nazionale Tumori "Fondazione Pascale" Napoli
City
Napoli
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonello Pinto
First Name & Middle Initial & Last Name & Degree
Antonello Pinto
Facility Name
Azienda Ospedaliera San Camillo Forlanini di Roma
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luigi Rigacci
First Name & Middle Initial & Last Name & Degree
Luigi Rigacci
Facility Name
IRCCS San Raffaele Scientific Institute
City
Segrate
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andres Ferreri
Email
Ferreri.AndresJ.M@hsr.it
First Name & Middle Initial & Last Name & Degree
Andres Ferreri
Facility Name
Azienda Sanitaria Universitaria Integrata di Trieste
City
Trieste
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Zaja
First Name & Middle Initial & Last Name & Degree
Francesco Zaja
Facility Name
Azienda Sanitaria Universitaria Integrata di Udine
City
Udine
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefano Volpetti
First Name & Middle Initial & Last Name & Degree
Stefano Volpetti
Facility Name
Azienda Ospedaliera Universitaria Integrata Verona
City
Verona
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlo Visco
First Name & Middle Initial & Last Name & Degree
Carlo Visco
Facility Name
Haukeland Universitetshospital
City
Bergen
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Öystein Fluge
Email
oystein.fluge@helse-bergen.no
First Name & Middle Initial & Last Name & Degree
Öystein Fluge
Facility Name
Kalnes Hospital (Østfold)
City
Grålum
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dlawer Barzenje
Email
Dlawer.Barzenje@so-hf.no
First Name & Middle Initial & Last Name & Degree
Dlawer Barzenje
Facility Name
Akershus University Hospital
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Adele Mastroianni
Email
maria.adele.mastroianni@ahus.no
First Name & Middle Initial & Last Name & Degree
Maria Adele Mastroianni
Facility Name
Avd. for Kreftbehandling, Oslo universitetssykehus
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Harald Holte
Email
hhe@ous-hf.no
First Name & Middle Initial & Last Name & Degree
Harald Holte
Facility Name
Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus
City
Stavanger
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Waleed Majeed Mohammed
Email
waleed.majeed.mohammed@sus.no
First Name & Middle Initial & Last Name & Degree
Waleed Majeed Mohammed
Facility Name
University Hospital of North Norway
City
Tromsø
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanne Bersvendsen
Email
hanne.bersvendsen@unn.no
First Name & Middle Initial & Last Name & Degree
Hanne Bersvendsen
Facility Name
Kreftklinikken, St Olavs Hospital
City
Trondheim
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Unn Merete Fagerli
Email
unn.merete.fagerli@stolav.no
First Name & Middle Initial & Last Name & Degree
Unn Merete Fagerli
Facility Name
Sykehuset i Vestfold
City
Tønsberg
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marit Rinde
Email
MRIN@siv.no
First Name & Middle Initial & Last Name & Degree
Marit Rinde
Facility Name
Medicinkliniken, Södra Älvsborg Sjukhus
City
Borås
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per-Ola Andersson
Email
per-ola.andersson@vgregion.se
First Name & Middle Initial & Last Name & Degree
Per-Ola Andersson
Facility Name
Department of Hematology and Coagulation, Sahlgrenska University Hospital
City
Göteborg
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariana Villegas Scivetti
Email
mariana.villegas@vgregion.se
First Name & Middle Initial & Last Name & Degree
Mariana Villegas Scivetti
Facility Name
Department of Medicine, Halmstad Country Hospital
City
Halmstad
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nevzeta Kuric
Email
nevzeta.kuric@regionhalland.se
First Name & Middle Initial & Last Name & Degree
Nevzeta Kuric
Facility Name
Department of Internal Medicine, Kalmar County Hospital
City
Kalmar
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fredrik Ellin
Email
fredrik.ellin@med.lu.se
First Name & Middle Initial & Last Name & Degree
Fredrik Ellin
Facility Name
Hematologiska Kliniken, Universitetssjukhuset
City
Linköping
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingemar Lagerlöf
Email
ingemar.lagerlof@regionostergotland.se
First Name & Middle Initial & Last Name & Degree
Ingemar Lagerlöf
Facility Name
Department of Oncology, Skåne University Hospital
City
Lund
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman
Email
mats.jerkeman@med.lu.se
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman
Facility Name
Center of Hematology, Karolinska University Hospital
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Harrysson
Email
sara.harrysson@sll.se
First Name & Middle Initial & Last Name & Degree
Sara Harrysson
Facility Name
Department of Medicine, Sunderbyn Hospital
City
Södra Sunderbyn
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lena Brandefors
Email
lena.brandefors@norrbotten.se
First Name & Middle Initial & Last Name & Degree
Lena Brandefors
Facility Name
Uddevalla Sjukhus
City
Uddevalla
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lina Wide
Email
lina.wide@vgregion.se
First Name & Middle Initial & Last Name & Degree
Lina Wide
Facility Name
Cancercentrum, Norrlands universitetsjukhus
City
Umeå
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Sjöström
Email
sara.sjostrom@regionvasterbotten.se
First Name & Middle Initial & Last Name & Degree
Sara Sjöström
Facility Name
Department of Oncology, Uppsala Academic Hospital
City
Uppsala
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Hagberg
Email
hans.hagberg@akademiska.se
First Name & Middle Initial & Last Name & Degree
Hans Hagberg
Facility Name
Varberg Hospital
City
Varberg
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carl Simonson
Email
Carl.Simonson@regionhalland.se
First Name & Middle Initial & Last Name & Degree
Carl Simonsen
Facility Name
Department of Oncology, Örebro University Hospital
City
Örebro
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Urban Jerlström
Email
urban.jerlstrom@regionorebrolan.se
First Name & Middle Initial & Last Name & Degree
Urban Jerlström

12. IPD Sharing Statement

Learn more about this trial

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

We'll reach out to this number within 24 hrs